

To: Brad Arington[barington@theranos.com]
From: Sunil Dhawan
Sent: Tue 11/25/2014 4:04:10 PM
Importance: Normal
Subject: Re: Follow-up on VMs
Received: Tue 11/25/2014 4:03:15 PM

yes- we perform histopathology- interpretation of slides. Call me at 1 Pm on my cell- left you a vm this am
Sunil S. Dhawan, MD
Center for Dermatology, Inc.
Center for Dermatology Clinical Research, Inc.
-Office-MWF
-Office-TTh

- email

www.centerforderm.com- main practice site
www.ctr4derm.com- clinical research site

On Monday, November 24, 2014 7:11 PM, Brad Arington <barington@theranos.com> wrote:

Sunil:

One thing I wanted to follow-up on from our conversation this morning. The following information is provided about the CLIA classification of complexity and I wanted to verify that your lab performs those tests included in the high complexity description below.

Waived– simple tests that do not require additional quality assessment (for a list of these tests, see www.cms.hhs.gov/CLIA/downloads/waivetbl.pdf).

Moderate Complexity– most automated tests that do not meet the waiver criteria (e.g. KOH exams, Tzanck smears, fungal cultures with DTM, and staining procedures) or provider-performed microscopy procedures (PPMP).

High Complexity– non-automated tests (e.g. histopathology, Mohs surgery, cytodagnosis of molluscum contagiosum, and microscopic hair shaft evaluation).

Thanks, Brad

Brad Arington

Theranos, Inc.

Senior Regulatory Counsel

Direct: (650) 856-7304

Cell:

CTRL-DHAWAN-00007615

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto.

From:Brad Arington
Sent: Monday, November 24, 2014 5:31 PM
To: 'Sunil Dhawan'
Subject: RE: Follow-up on VMs

Sunil:

Thanks for taking the time to talk with me today. I do have one follow-up question for you if you're free this evening. Just let me know a good time to call you or you can reach me at my office.

Thanks,

Brad

Brad Arington

Theranos, Inc.

Senior Regulatory Counsel

Direct: (650) 856-7304

Cell:

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto.

From:Sunil Dhawan [<mailto:sdhaw@>]
Sent: Sunday, November 23, 2014 8:56 PM
To: Brad Arington
Subject: Re: Follow-up on VMs

let talk on tuesday at 1 pm.my cell

CTRL-DHAWAN-00007615

Sunil Dhawan

On Saturday, November 22, 2014 2:15 PM, Brad Arington <barington@theranos.com> wrote:

Sorry about that. I had something to go out for in the late morning early afternoon and had forgotten to take my phone with me. I have a couple of things that I need to follow-up on over the next hour or so and then I'll be free. Let me know if there may be a good time later today or tomorrow we could talk since Monday is likely to be busy for both of us.

Brad Arington

Theranos, Inc.

Senior Regulatory Counsel

Direct: (650) 856-7304

Cell:

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto.

From: Sunil Dhawan [<mailto:sdhaw@>]
Sent: Saturday, November 22, 2014 10:25 AM
To: Brad Arington
Subject: Re: Follow-up on VMs

Tried u again

What is a good time to talk,

Sunil Dhawan

Sent from my iPad

On Nov 22, 2014, at 5:58 AM, Sunil Dhawan <sdhaw@> wrote:

I have 24 years of interpreting histopathologic slides, fungal cultures, smears

Let's talk on Monday .

CTRL-DHAWAN-00007615

I tried your cell, but vm not set up yet

Sorry about last 2days-been very busy

Will try u today as well

Best time to talk is after 5 pm or 1230-130

Sunil Dhawan

Sent from my iPad

On Nov 21, 2014, at 4:02 PM, Brad Arington <barington@theranos.com> wrote:

Dr. Dhawan:

I just wanted to follow-up by email on the voicemails that I left you. I received your paperwork from Ariel and that all looks good. I did want to follow-up on the experience requirement under CLIA for lab director that I had mentioned before, as this will have to be submitted along with the paperwork. I have the copy of your M.D., verification of state license and copy of your board certification in dermatology. The one other thing that we need to submit is confirmation of your lab experience through one of the two paths below.

- o Have at least one year of laboratory training during medical residency (for example, physicians certified either in hematology or hematology and medical oncology by the American Board of Internal Medicine – see additional information from the Interpretive Guidelines below on Residency Training); or
- o (ii) Have at least 2 years of experience directing or supervising high complexity testing (see additional information from the Interpretive Guidelines on Training and Experience below)

I also have your lab's CLIA certificate. If your lab is certified as a high complexity lab, then we will just need the dates that you've been lab director there.

Thanks for your assistance.

Regards,

Brad Arington

Theranos, Inc.

Senior Regulatory Counsel

Direct: (650) 856-7304

Cell:

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto.